Keyword: Regeneron Pharmaceuticals
Roche's antibody RG7716 in diabetic macular edema could be a threat to current blockbuster VEGF drugs used for the disease.
AstraZeneca and Amgen’s tezepelumab missed the primary endpoint in a phase 2a atopic dermatitis trial, raising doubts about its prospects.
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
Teva will pay $250 million to help finish off mid-to-late stage work and then team up on selling Regeneron's experimental NGF antibody fasinumab.
The Medicines Company will have to continue on with a study for its investigational heart drug after an independent body said early data were not strong enough to stop the test early.
Pfizer has posted positive data from two more trials for its new experimental anticholesterol drug bococizumab as the three-way dual for the PCSK9 inhibitor market heats up.
Regeneron and Sanofi have added another big piece to the late-stage data puzzle for dupilumab, which could be approved and launched in early 2017.